Research programme: checkpoint kinase 1 inhibitors - VernalisAlternative Names: V 158411
Latest Information Update: 10 Apr 2012
At a glance
- Originator Vernalis
- Mechanism of Action Checkpoint kinase 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Apr 2012 V 158411 is available for partnering (www.vernalis.com)
- 27 Aug 2010 Preclinical development is ongoing in United Kingdom
- 19 Nov 2009 Preclinical pharmacodynamics, pharmacokinetics and safety data in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)